101 related articles for article (PubMed ID: 31594427)
1. Effects of guluronic acid (G2013) on gene expression of TLR2, TLR4, MyD88, TNF-α and CD52 in multiple sclerosis under in vitro conditions.
Noorbakhsh SM; Razavi A; Moghadam NB; Saadat P; Hoseini M; Aghazadeh Z; Mobini M; Oraei M; Mirshafiey A
Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):586-590. PubMed ID: 31594427
[No Abstract] [Full Text] [Related]
2. Immunomodulatory Effect of G2013 (α-L-Guluronic Acid) on the TLR2 and TLR4 in Human Mononuclear Cells.
Sharifi L; Mohsenzadegan M; Aghamohammadi A; Rezaei N; Zavareh FT; Bokaie S; Moshiri M; Aghazadeh Z; Norouzbabaie Z; Azizi G; Mirshafiey A
Curr Drug Discov Technol; 2018; 15(2):123-131. PubMed ID: 28578651
[TBL] [Abstract][Full Text] [Related]
3. The Immunomodulatory Role of G2013 (α-L-Guluronic Acid) on the Expression of TLR2 and TLR4 in HT29 cell line.
Farhang H; Sharifi L; Dallal MMS; Moshiri M; Norouzbabaie Z; Bokaie S; Aletaha S; Zargar SJ; Mirshafiey A
Curr Drug Discov Technol; 2019; 16(1):91-95. PubMed ID: 29484999
[TBL] [Abstract][Full Text] [Related]
4. Antagonistic Property of G2013 (α-L-Guluronic Acid) on Gene Expression of MyD88, Tollip, and NF-κB in HEK293 TLR2 and HEK293 TLR4.
Sharifi L; Aghamohammadi A; Aletaha S; Bigdeli R; Asgary V; Bokaie S; Asgardoon MH; Azizi G; Mirshafiey A
Endocr Metab Immune Disord Drug Targets; 2019; 19(2):144-149. PubMed ID: 30784390
[TBL] [Abstract][Full Text] [Related]
5. Effects of guluronic acid (G2013) on SHIP1, SOCS1 induction and related molecules in TLR4 signaling pathway.
Mortazavi-Jahromi SS; Farazmand A; Motamed N; Navabi SS; Mirshafiey A
Int Immunopharmacol; 2018 Feb; 55():323-329. PubMed ID: 29310108
[TBL] [Abstract][Full Text] [Related]
6. The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under
Tahmasebi S; Neishaboori H; Jafari D; Faghihzadeh E; Esmaeilzadeh A; Mirshafiey A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):562-570. PubMed ID: 34314306
[TBL] [Abstract][Full Text] [Related]
7. Pivotal cytokines and their transcription factors are the targets of guluronic acid (G2013) for inhibiting the immunopathogenesis process of multiple sclerosis.
Hossein-Khannazer N; Shabani S; Farokhfar M; Azizi G; Asarzadegan F; Safarpour Lima B; Mirshafeiey A
Drug Dev Res; 2020 Jun; 81(4):511-516. PubMed ID: 32103523
[TBL] [Abstract][Full Text] [Related]
8. Effect of Guluronic Acid (G2013), As a New Anti-inflammatory Drug on Gene Expression of Pro-inflammatory and Anti-inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients.
Bakhtiari T; Azarian S; Ghaderi A; Ahmadzadeh A; Mirshafiey A
Iran J Allergy Asthma Immunol; 2019 Nov; 18(6):639-648. PubMed ID: 32245307
[TBL] [Abstract][Full Text] [Related]
9. Interferon-Beta Treatment Differentially Alters TLR2 and TLR4-Dependent Cytokine Production in Multiple Sclerosis Patients.
Oliveira IBN; Gomes RS; Gomides LF; Dos Santos JC; Carneiro MAD; Ribeiro-Dias F; Diniz DS
Neuroimmunomodulation; 2019; 26(2):77-83. PubMed ID: 30897575
[TBL] [Abstract][Full Text] [Related]
10. Biologically relevant doses of mixed aflatoxins B and G up-regulate MyD88, TLR2, TLR4 and CD14 transcripts in human PBMCs.
Malvandi AM; Mehrzad J; Saleh-moghaddam M
Immunopharmacol Immunotoxicol; 2013 Aug; 35(4):528-32. PubMed ID: 23786414
[TBL] [Abstract][Full Text] [Related]
11. Hepatic TLR2 & TLR4 expression correlates with hepatic inflammation and TNF-α in HCV & HCV/HIV infection.
Berzsenyi MD; Roberts SK; Preiss S; Woollard DJ; Beard MR; Skinner NA; Bowden DS; Visvanathan K
J Viral Hepat; 2011 Dec; 18(12):852-60. PubMed ID: 21050341
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property.
Mirshafiey A; Mortazavi-Jahromi SS; Taeb M; Cuzzocrea S; Esposito E
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):162-168. PubMed ID: 29879894
[TBL] [Abstract][Full Text] [Related]
13. Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties.
Mortazavi-Jahromi SS; Nazeri S; Jafarnezhad-Ansariha F; Oraei M; Mirshafiey A
Immunol Res; 2019 Feb; 67(1):108-115. PubMed ID: 30474833
[TBL] [Abstract][Full Text] [Related]
14. An in vitro evaluation of anti-aging effect of guluronic acid (G2013) based on enzymatic oxidative stress gene expression using healthy individuals PBMCs.
Taeb M; Mortazavi-Jahromi SS; Jafarzadeh A; Mirzaei MR; Mirshafiey A
Biomed Pharmacother; 2017 Jun; 90():262-267. PubMed ID: 28364598
[TBL] [Abstract][Full Text] [Related]
15. Evaluating Mannuronic Acid Effect on Gene Expression Profile of Inflammatory Mediators in Rheumatoid Arthritis Patients.
Omidian S; Aghazadeh Z; Ahmadzadeh A; Aslani M; Hosseini M; Abbasi S; Mirshafiey A
Iran J Allergy Asthma Immunol; 2022 Feb; 21(1):44-54. PubMed ID: 35524377
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of G2013 (α-L-guluronic acid) efficacy on PC-3 cells through inhibiting the expression of inflammatory factors.
Bagherian Z; Mirshafiey A; Mohsenzadegan M; Farajollahi MM
Clin Exp Pharmacol Physiol; 2022 Feb; 49(2):254-263. PubMed ID: 34699087
[TBL] [Abstract][Full Text] [Related]
17. M2000 (β-D-Mannuronic Acid) as a Novel Antagonist for Blocking the TLR2 and TLR4 Downstream Signalling Pathway.
Aletaha S; Haddad L; Roozbehkia M; Bigdeli R; Asgary V; Mahmoudi M; Mirshafiey A
Scand J Immunol; 2017 Feb; 85(2):122-129. PubMed ID: 27943385
[TBL] [Abstract][Full Text] [Related]
18. Effects of guluronic acid, as a new NSAID with immunomodulatory properties on IL-17, RORγt, IL-4 and GATA-3 gene expression in rheumatoid arthritis patients.
Khadem Azarian S; Jafarnezhad-Ansariha F; Nazeri S; Azizi G; Aghazadeh Z; Hosseinzadeh E; Mirshafiey A
Immunopharmacol Immunotoxicol; 2020 Feb; 42(1):22-27. PubMed ID: 31856612
[No Abstract] [Full Text] [Related]
19. Increased TLR2 expression in patients with type 1 diabetes: evidenced risk of microalbuminuria.
Ururahy MA; Loureiro MB; Freire-Neto FP; de Souza KS; Zuhl I; Brandão-Neto J; Hirata RD; Doi SQ; Arrais RF; Hirata MH; Almeida Md; de Rezende AA
Pediatr Diabetes; 2012 Mar; 13(2):147-54. PubMed ID: 21848584
[TBL] [Abstract][Full Text] [Related]
20. The Evaluation of Safety Property and Apoptotic Efficacy of α-L-Guluronic Acid (G2013), as a Novel NSAID, Under
Hassani S; Afshari JT; Jafarnezhad-Ansariha F; Mirshafiey A
Recent Adv Inflamm Allergy Drug Discov; 2022; 15(1):9-15. PubMed ID: 34503439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
